{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:27:58Z","timestamp":1790792878442,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Danube University Krems University for Continuing Education"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40263-021-00855-4","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T10:10:47Z","timestamp":1631095847000},"page":"1053-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-3678","authenticated-orcid":false,"given":"Gerald","family":"Gartlehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Crotty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Edlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Fortman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Wines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Persad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"issue":"9759","key":"855_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(10)61422-5","volume":"377","author":"F Leichsenring","year":"2011","unstructured":"Leichsenring F, et al. Borderline personality disorder. Lancet. 2011;377(9759):74\u201384.","journal-title":"Lancet"},{"issue":"1","key":"855_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1176\/appi.ajp.163.1.20","volume":"163","author":"JM Oldham","year":"2006","unstructured":"Oldham JM. Borderline personality disorder and suicidality. Am J Psychiatry. 2006;163(1):20\u20136.","journal-title":"Am J Psychiatry"},{"key":"855_CR3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). Washington D.C.: American Psychiatric Publishing; 2013. p. 645, 663\u20136.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"855_CR4","unstructured":"World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders. World Health Organization. 1993 April 3, 2021. https:\/\/www.who.int\/classifications\/icd\/en\/bluebook.pdf."},{"issue":"1","key":"855_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/S0954579411000812","volume":"24","author":"DW Belsky","year":"2012","unstructured":"Belsky DW, et al. Etiological features of borderline personality related characteristics in a birth cohort of 12-year-old children. Dev Psychopathol. 2012;24(1):251\u201365.","journal-title":"Dev Psychopathol"},{"key":"855_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.copsyc.2017.11.010","volume":"21","author":"C Sharp","year":"2018","unstructured":"Sharp C, Wall K. Personality pathology grows up: adolescence as a sensitive period. Curr Opin Psychol. 2018;21:111\u20136.","journal-title":"Curr Opin Psychol"},{"issue":"8","key":"855_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/archgenpsychiatry.2011.37","volume":"68","author":"JG Gunderson","year":"2011","unstructured":"Gunderson JG, et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry. 2011;68(8):827\u201337.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"855_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pmh.1331","volume":"10","author":"IJ Niesten","year":"2016","unstructured":"Niesten IJ, et al. Description and prediction of the income status of borderline patients over 10 years of prospective follow-up. Personal Ment Health. 2016;10(4):285\u201392.","journal-title":"Personal Ment Health"},{"key":"855_CR9","doi-asserted-by":"crossref","unstructured":"Paris J. Suicidality in borderline personality disorder. Medicina (Kaunas). 2019;55(6).","DOI":"10.3390\/medicina55060223"},{"issue":"2","key":"855_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1192\/bjp.2019.166","volume":"216","author":"C Winsper","year":"2020","unstructured":"Winsper C, et al. The prevalence of personality disorders in the community: a global systematic review and meta-analysis. Br J Psychiatry. 2020;216(2):69\u201378.","journal-title":"Br J Psychiatry"},{"key":"855_CR11","unstructured":"Torgersen J. Epidemiology. W: J. Oldham, AE Skodol i DS Bender (red.), Textbook of personality disorders (s. 129-141). Washington, DC: American Psychiatric Publishing; 2005."},{"issue":"5","key":"855_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1176\/appi.ajp.2009.08121825","volume":"166","author":"JG Gunderson","year":"2009","unstructured":"Gunderson JG. Borderline personality disorder: ontogeny of a diagnosis. Am J Psychiatry. 2009;166(5):530\u20139.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"855_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/archinte.162.1.53","volume":"162","author":"R Gross","year":"2002","unstructured":"Gross R, et al. Borderline personality disorder in primary care. Arch Intern Med. 2002;162(1):53\u201360.","journal-title":"Arch Intern Med"},{"issue":"5","key":"855_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/acps.13094","volume":"140","author":"LH Hastrup","year":"2019","unstructured":"Hastrup LH, et al. Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses. Acta Psychiatr Scand. 2019;140(5):458\u201367.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"855_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1521\/pedi_2012_26_093","volume":"28","author":"RL Tomko","year":"2014","unstructured":"Tomko RL, et al. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord. 2014;28(5):734\u201350.","journal-title":"J Pers Disord"},{"key":"855_CR16","unstructured":"Australian Government National Health and Medical Research Council. Clinical practice guideline for the management of borderline personality disorder. 2012 January 14, 2021. https:\/\/bpdfoundation.org.au\/images\/mh25_borderline_personality_guideline.pdf."},{"key":"855_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-019-0106-3","volume":"6","author":"S Simonsen","year":"2019","unstructured":"Simonsen S, et al. European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregul. 2019;6:9.","journal-title":"Borderline Personal Disord Emot Dysregul"},{"key":"855_CR18","unstructured":"National Collaborating Centre for Mental Health. Borderline Personality Disorder: The NICE Guideline on Treatment and Management. 2018 August 2018 [cited 2021 14 January]. https:\/\/www.nice.org.uk\/guidance\/cg78\/evidence\/bpd-full-guideline-242147197."},{"issue":"10 Suppl","key":"855_CR19","first-page":"1","volume":"158","author":"American Psychiatric Association","year":"2001","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158(10 Suppl):1\u201352.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"855_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","volume":"25","author":"R Bridler","year":"2015","unstructured":"Bridler R, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25(6):763\u201372.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"855_CR21","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.4088\/JCP.14m09228","volume":"76","author":"C Paton","year":"2015","unstructured":"Paton C, et al. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76(4):e512\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"855_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13651501.2019.1576904","volume":"23","author":"F Riffer","year":"2019","unstructured":"Riffer F, et al. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract. 2019;23(3):178\u201388.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"1","key":"855_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JCP.0000000000000232","volume":"35","author":"MC Zanarini","year":"2015","unstructured":"Zanarini MC, et al. Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up. J Clin Psychopharmacol. 2015;35(1):63\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"855_CR24","unstructured":"National Institute for Health and Clinical Excellence. Borderline personality disorder: recognition and management. 2015 April 3, 2021. https:\/\/www.nice.org.uk\/guidance\/CG78\/documents\/cg78-borderlinepersonality-disorder-bpd-surveillance-review-decision-january-20153."},{"key":"855_CR25","unstructured":"National Health and Medical Research Council. Clinical Practice Guideline for the Management of Borderline Personality Disorder. 2012 April 3, 2021. https:\/\/www.nhmrc.gov.au\/about-us\/publications\/clinical-practice-guideline-borderline-personality-disorder."},{"key":"855_CR26","unstructured":"American Psychiatric Association. PRACTICE GUIDELINE FOR THE Treatment of Patients with Borderline Personality Disorder. April 5, 2021. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/bpd.pdf."},{"issue":"4","key":"855_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/15622970701685224","volume":"8","author":"SC Herpertz","year":"2007","unstructured":"Herpertz SC, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007;8(4):212\u201344.","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"855_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.9758\/cpn.2021.19.1.53","volume":"19","author":"J Schulkens","year":"2021","unstructured":"Schulkens J, et al. Selective serotonin reuptake-inhibitors for symptom-based treatment of borderline personality disorders in older adults: an International Delphi Study. Clin Psychopharmacol Neurosci. 2021;19(1):53\u201362.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"855_CR29","doi-asserted-by":"crossref","unstructured":"Stoffers J, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):Cd005653.","DOI":"10.1002\/14651858.CD005653.pub2"},{"issue":"5","key":"855_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40263-017-0425-0","volume":"31","author":"E Hancock-Johnson","year":"2017","unstructured":"Hancock-Johnson E, Griffiths C, Picchioni M. A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs. 2017;31(5):345\u201356.","journal-title":"CNS Drugs"},{"issue":"8","key":"855_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11920-020-01164-1","volume":"22","author":"J Stoffers-Winterling","year":"2020","unstructured":"Stoffers-Winterling J, Storeb\u00f8 OJ, Lieb K. Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Rep. 2020;22(8):37.","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"855_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"855_CR33","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"1","key":"855_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0266462311000687","volume":"28","author":"G Gartlehner","year":"2012","unstructured":"Gartlehner G, et al. Clinical heterogeneity in systematic reviews and health technology assessments: synthesis of guidance documents and the literature. Int J Technol Assess Health Care. 2012;28(1):36\u201343.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"855_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"855_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0269881105051540","volume":"19","author":"K Tritt","year":"2005","unstructured":"Tritt K, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19(3):287\u201391.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"855_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/01.jcp.0000195113.61291.48","volume":"26","author":"TH Loew","year":"2006","unstructured":"Loew TH, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26(1):61\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"855_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","volume":"163","author":"MK Nickel","year":"2006","unstructured":"Nickel MK, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163(5):833\u20138.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"855_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.biopsych.2004.11.044","volume":"57","author":"MK Nickel","year":"2005","unstructured":"Nickel MK, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57(5):495\u20139.","journal-title":"Biol Psychiatry"},{"issue":"11","key":"855_CR40","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.4088\/JCP.v65n1112","volume":"65","author":"MK Nickel","year":"2004","unstructured":"Nickel MK, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65(11):1515\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"855_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1176\/appi.ajp.2014.13101348","volume":"171","author":"DW Black","year":"2014","unstructured":"Black DW, et al. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171(11):1174\u201382.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"855_CR42","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1176\/appi.ajp.2018.17091006","volume":"175","author":"MJ Crawford","year":"2018","unstructured":"Crawford MJ, et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry. 2018;175(8):756\u201364.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"855_CR43","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4088\/JCP.v65n0704","volume":"65","author":"MC Zanarini","year":"2004","unstructured":"Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65(7):903\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"855_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.4088\/JCP.08m04138yel","volume":"72","author":"MC Zanarini","year":"2011","unstructured":"Zanarini MC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72(10):1353\u201362.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"855_CR45","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4088\/JCP.v62n1103","volume":"62","author":"MC Zanarini","year":"2001","unstructured":"Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62(11):849\u201354.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"855_CR46","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","volume":"162","author":"J Soler","year":"2005","unstructured":"Soler J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162(6):1221\u20134.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"855_CR47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4088\/JCP.v65n0314","volume":"65","author":"EB Simpson","year":"2004","unstructured":"Simpson EB, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65(3):379\u201385.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"855_CR48","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","volume":"193","author":"SC Schulz","year":"2008","unstructured":"Schulz SC, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193(6):485\u201392.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"855_CR49","first-page":"270","volume":"24","author":"DB Reich","year":"2009","unstructured":"Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24(5):270\u20135.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"855_CR50","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4088\/JCP.v69n0412","volume":"69","author":"JC Pascual","year":"2008","unstructured":"Pascual JC, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008;69(4):603\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"855_CR51","first-page":"255","volume":"24","author":"R Moen","year":"2012","unstructured":"Moen R, et al. Efficacy of extended-release divalproex combined with \u201ccondensed\u201d dialectical behavior therapy for individuals with borderline personality disorder. Ann Clin Psychiatry. 2012;24(4):255\u201360.","journal-title":"Ann Clin Psychiatry"},{"issue":"6","key":"855_CR52","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4088\/JCP.v69n0617","volume":"69","author":"MM Linehan","year":"2008","unstructured":"Linehan MM, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69(6):999\u20131005.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"855_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4088\/JCP.v62n0311","volume":"62","author":"E Hollander","year":"2001","unstructured":"Hollander E, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62(3):199\u2013203.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"855_CR54","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4088\/JCP.v63n0511","volume":"63","author":"FR Frankenburg","year":"2002","unstructured":"Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63(5):442\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"855_CR55","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40263-017-0458-4","volume":"31","author":"P Bozzatello","year":"2017","unstructured":"Bozzatello P, et al. Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial. CNS Drugs. 2017;31(9):809\u201319.","journal-title":"CNS Drugs"},{"issue":"1","key":"855_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4088\/JCP.v65n0118","volume":"65","author":"MP Bogenschutz","year":"2004","unstructured":"Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65(1):104\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"855_CR57","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00213-007-0740-0","volume":"191","author":"MK Nickel","year":"2007","unstructured":"Nickel MK, Loew TH, Pedrosa Gil F. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology. 2007;191(4):1023\u20136.","journal-title":"Psychopharmacology"},{"key":"855_CR58","unstructured":"National Institute of Mental Health (NIMH). Treating suicidal behavior and self-mutilation in people with borderline personality disorder. 2007, May 15, 2021. https:\/\/clinicaltrials.gov\/show\/NCT00533117."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00855-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00855-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00855-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T03:25:55Z","timestamp":1675653955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00855-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00855-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"8 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Open access funding provided by Danube University Krems University for Continuing Education. This research was funded by the American Psychiatric Association.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Data for meta-analyses will be provided upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Acquiring of funding: GG, MV, KC; Protocol development: GG, MV, KC, ME; Title and abstract screening: GG, MV, SK, KC, EP, RW, RA, RF, MS; Data extraction: RW, RA, RF, MS; Interpretation of findings: GG, MV, KC; Draft manuscript: GG, SK, ME; Final revision of manuscript: all authors. Approval for publication: all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}